{"entity":{"id":"mabswitch","kind":"company","name":"Mabswitch","aka":["MabSwitch, Inc."],"tldr":"Mabswitch is a Los Angeles-area company making antibodies whose strength of binding can be turned up or down by a second, small molecule after they are given. It is applying the idea to CAR-T cells and antibody-drug conjugates for cancer.","summary":"MabSwitch, Inc. develops ligand-programmable antibodies designed to give control over their activity after administration, and applies them to switchable-affinity T-cell engagers, antibody-drug conjugates and CAR-T cells, according to its website. In 2026 it received two National Cancer Institute SBIR awards: one for a remote-controlled peptide-centric CAR T-cell therapy for solid tumours, whose abstract names neuroblastoma as an example of a low-mutational-burden cancer, and one for an affinity-tunable antibody-drug conjugate against high-grade serous ovarian cancer. All of its programmes are preclinical.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://mabswitch.com/"},{"label":"Pipeline","url":"https://mabswitch.com/products/"},{"label":"NIH RePORTER: award 1R43CA310118-01","url":"https://reporter.nih.gov/project-details/11313251"},{"label":"NIH RePORTER: award 1R43CA314526-01","url":"https://reporter.nih.gov/project-details/11405623"}],"tags":[],"related":[],"cancers":["ovarian","neuroblastoma"],"sections":["immunotherapy","adcs","cell-therapy"],"technologies":["car-t","adc","t-cell-engager"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website (home and pipeline pages) and the NIH RePORTER records read on 4 November 2026. No named product candidate is given on the website."],"hq":"Van Nuys, CA","country":"US","companyType":"biotech","website":"https://mabswitch.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":399998,"source":"https://reporter.nih.gov/project-details/11313251","note":"NCI SBIR (R43) award 1R43CA310118-01: Remote-Controlled PC-CAR T-Cell Therapy for Hard-to-Treat Solid Tumors"},{"round":"Grant","year":2026,"amountUsd":399992,"source":"https://reporter.nih.gov/project-details/11405623","note":"NCI SBIR (R43) award 1R43CA314526-01: Affinity-tunable Antibody Drug Conjugate (ADC) against High-Grade Serous Ovarian Cancer"}]},"route":"/companies/mabswitch/","neighbours":{"cancer":[{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}]}}